Argenx to Discontinue Late-Stage Sjogren's Disease Trial; Shares Down Pre-Bell
MT newswire2026/10/08 08:3804:38 AM EDT, 10/08/2026 (MT Newswires) -- Argenx (ARGX) will discontinue a phase 3 study of efgartigimod subcutaneous in adults with moderate-to-severe Sjogren's disease after an independent data monitoring committee recommended stopping the trial for futility, the company said Thursday. The committee concluded that the study was unable to meet its primary endpoint, while safety remained consistent with efgartigimod's established profile, according to the company. Separately, Argenx said a phase 2 study of FB102 in adults with celiac disease met its primary endpoint, showing a "statistically significant and clinically relevant" treatment effect, compared with placebo. The observed safety profile was consistent with previous studies and the known safety profile of FB102, with no new safety signals identified. The company plans to advance FB102 into phase 3 development, it said. Sjogren's disease is a chronic, slowly progressive, inflammatory systemic autoimmune disease characterized by destruction of the exocrine glands. Celiac disease is a chronic autoimmune condition that can lead to impaired nutrient absorption. Argenx shares were down nearly 17% in premarket activity.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Google (GOOGL.US) warns that new Australian cybersecurity regulations may cut off minors' access to Gmail
Google stated that a new cybersecurity bill in Australia could prevent minors from using Gmail.
Canaccord Genuity: Lowers Oklo's target price to $66
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.
Dental treatment company vVardis has announced the terms for its $214 million US IPO.
Crypto prices
More
